Christopher Freeburn

InvestorPlace Writer

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

Friday Apple Rumors: Updated iPad for Christmas

By Christopher Freeburn, InvestorPlace Writer Jul 6, 2012

A slimmer iPad with better battery life will be released by Christmas; the iPhone 5 will feature quad-core chips; and Apple shares could hit $1,001.

SEC Approves NYSE ‘Dark Pool’ Program

By Christopher Freeburn, InvestorPlace Writer Jul 6, 2012

The New York Stock Exchange has received SEC approval to launch a "dark pool" test program under which certain orders will not be displayed.

Is Amazon Preparing to Take on the iPhone?

By Christopher Freeburn, InvestorPlace Writer Jul 6, 2012

Internet retail giant Amazon is reportedly preparing to debut its own smartphone, aimed squarely at Apple's iPhone and phones using Google's Android OS.

Netflix Reaches Major Streaming Milestone

By Christopher Freeburn, InvestorPlace Writer Jul 5, 2012

Netlflix subscribers watched more than 1 billion hours of streaming video content in June as the company moves away from DVDs-by-mail service.

Tuesday Apple Rumors: New iMacs to Debut in October

By Christopher Freeburn, InvestorPlace Writer Jul 3, 2012

Apple is preparing upgraded iMacs for October launch; the iPad will lead tablet sales past notebooks by 2016; and a judge refuses to lift Galaxy Tab sales ban.

Automakers Post Strong Sales in June

By Christopher Freeburn, InvestorPlace Writer Jul 3, 2012

Automobile manufacturers reported strong June sales in the U.S., with GM, Ford, Chrysler, Toyota, Nissan and Volkswagen all reporting gains.

Glaxo to Pay $3B in Fines for Improper Drug Marketing

By Christopher Freeburn, InvestorPlace Writer Jul 3, 2012

GlaxoSmithKline will pay $3 billion in fines relating to its promotion of the antidepressant drugs, Paxil, Wellbutrin and Avandia, and the asthma drug Advair.